|
Baseline characteristics
|
All subjects (N = 338)
|
Discovery cohort (N = 175)
|
Replication cohort (N = 163)
|
AMI (N = 60)
|
No AMI (N = 278)
|
P-value
|
|---|
|
Age (years)
|
62 ± 11
|
67 ± 10
|
56 ± 10
|
65 ± 11
|
61 ± 11
|
0.014
|
|
Male gender (%)
|
218 (65)
|
112 (64)
|
106 (65)
|
47 (78)
|
171 (62)
|
0.015
|
|
Caucasian race (%)
|
331 (98)
|
170 (97)
|
163 (100)
|
58 (97)
|
273 (99)
|
0.19
|
|
Systolic blood pressure (mmHg)
|
138 ± 23
|
142 ± 23
|
133 ± 21
|
135 ± 23
|
138 ± 23
|
0.36
|
|
BMI (kg/m2)
|
30 ± 7
|
29 ± 6
|
31 ± 8
|
29.6 ± 6.8
|
30.2 ± 7.0
|
0.53
|
|
Serum creatinine (mg/dl)
|
1.3 ± 1.1
|
1.3 ± 1.4
|
1.2 ± 0.7
|
1.6 ± 2.2
|
1.2 ± 0.7
|
0.009
|
|
Acute MI (%)
|
60 (18)
|
37 (21)
|
23 (14)
|
-
|
-
|
-
|
|
Old MI (%)
|
109 (32)
|
61 (35)
|
48 (30)
|
13 (22)
|
96 (35)
|
0.060
|
|
Current smoking (%)
|
73 (22)
|
34 (19)
|
39 (24)
|
8 (14)
|
65 (24)
|
0.09
|
|
Diabetes (%)
|
120 (36)
|
65 (37)
|
55 (34)
|
29 (48)
|
91 (33)
|
0.024
|
|
Hypertension (%)
|
258 (77)
|
142 (81)
|
116 (72)
|
46 (77)
|
212 (77)
|
0.98
|
|
Dyslipidemia (%)
|
263 (78)
|
133 (79)
|
102 (77)
|
47 (78)
|
216 (78)
|
0.95
|
|
Chronic heart failure (%)
|
76 (23)
|
41 (24)
|
35 (21)
|
15 (25)
|
61 (22)
|
0.61
|
|
LVEF (%)
|
54 ± 11
|
54 ± 11
|
54 ± 11
|
51 ± 11
|
54 ± 11
|
0.06
|
|
HDL (mg/dl)
|
43 ± 15
|
44 ± 14
|
41 ± 16
|
38 ± 14
|
44 ± 15
|
0.014
|
|
LDL (mg/dl)
|
92 ± 37
|
91 ± 36
|
94 ± 38
|
85 ± 33
|
94 ± 37
|
0.13
|
|
Triglyceride (mg/dl)
|
159 ± 115
|
150 ± 93
|
170 ± 137
|
154 ± 107
|
160 ± 117
|
0.73
|
|
Total cholesterol (mg/dl)
|
166 ± 45
|
164 ± 42
|
169 ± 48
|
153 ± 35
|
169 ± 47
|
0.02
|
|
History of CABG (%)
|
73 (21)
|
42 (24)
|
31 (19)
|
13 (22)
|
60 (22)
|
0.99
|
|
Gensini score
|
35 ± 54
|
38 ± 57
|
31 ± 55
|
48 ± 54
|
32 ± 54
|
0.046
|
|
Aspirin use (%)
|
83
|
131 (81)
|
131 (84)
|
48 (89)
|
214 (82)
|
0.2
|
|
Beta blocker use (%)
|
213 (67)
|
107 (67)
|
106 (67)
|
45 (82)
|
168 (64)
|
0.012
|
|
Clopidogrel use (%)
|
171 (55)
|
91 (56)
|
80 (53)
|
34 (64)
|
137 (53)
|
0.13
|
|
ACE-inh/ARB use (%)
|
192 (61)
|
100 (62)
|
92 (61)
|
35 (67)
|
157 (60)
|
0.35
|
|
Statin use (%)
|
244 (78)
|
129 (80)
|
115 (76)
|
44 (83)
|
200 (77)
|
0.33
|
|
>50% stenosis (in any major epicardial artery (%)
|
235 (70)
|
133 (76)
|
102 (64)
|
59 (93)
|
176 (64)
|
<0.001
|
- P-value denotes differences between those with and without AMI. Abbreviations: ACE-inh/ARB angiotensin converting enzyme inhibitor or angiotensin receptor blockers, BMI body mass index, CABG coronary artery bypass graft, HDLhigh-density lipoprotein, LDLlow-density lipoprotein, LVEF left ventricular ejection fraction, MI myocardial infarction.
